CARDIOVASCULAR
hamburger
BACK
product photo
product photo

DESIGNED TO BE THE MOST DELIVERABLE TAVI VALVE

The Portico self-expanding valve combines the quality of a surgical valve with the ease of a transcatheter approach—and with no need to remove the ineffective native valve.

Portico is also the lowest profile TAVI valve, now with a sheathless indication.1-3*

With Portico, implanters can tackle every case, even the most complex cases,1,4  without open-heart surgery. TAVI implemented with Portico also offers outstanding outcomes. 

*Based on internal testing. Tests performed by and data on file at Abbott.

OVERVIEW
FEATURES
EVIDENCE
ORDERING INFO

PORTICO'S UNIQUE PROPERTIES

The Portico transcatheter aortic valve has unique nitinol properties—the first TAVI valve that can be fully repositioned, recaptured, and retrieved prior to full deployment.5 Moreover, Portico’s unconstricted valve leaflet opening performs more like a natural heart valve.6


Portico design features


Other characteristics of the Portico transcatheter aortic valve include:

  • Bovine pericardium leaflets and Porcine pericardium sealing cuff treated with Linx anti-calcification treatment
  • Nonflared annulus portion of the stent frame
  • Optimal valve height

Aortic valve replacement with Portico also features minimal protrusion of the valve into the left ventricular outflow tract.


WATCH NOW

PORTICO PATIENT STORY

Gareth Hopkins Portico Patient Story

References

1. Søndergaard L. How Portico helps solve challenging cases: horizontal aorta and calcified annulus. Webinar March 4, 2016.
2. Data on file at Abbott. Document  90237740.
3. Taramasso M, Denegri A, Kuwata S, et al. Feasibility and safety of transfemoral sheathless Portico aortic valve implantation: preliminary results in a single center experience. Catheter Cardiovasc Interv. 2018;91(3):533-539. doi: 10.1002/ccd.27100.
4. Agnifili M, Brambilla N, Testa L, et al. Use of the Solopath re-collapsible balloon access system for troublesome femoral access with the Portico transcatheter valve. Radcliffe Cardiology. June 2015.
5. Möllmann H, Linke A, Holzhey DM, et al. Portico TF EU Pre-CE Mark 30-day outcomes for all 4 valve sizes. J Am Coll Cardiol Interv. 2017;10:1538–1547.
6. Bedogni F. Aortic Valve replacement. JESFC 2018.  

EXCELLENT FLEXIBILITY, DELIVERABILITY, AND HEMODYNAMIC PERFORMANCE

Portico, which has the lowest transcatheter aortic valve implantation (TAVI) profile1-3 offers flexibility and deliverability—enabling navigation even in tortuous anatomy.1,5

Portico's features include:

  • Preserves coronary access for potential future interventions—and therefore offers options to other treating physicians—thanks to Portico’s large open cell design6
  • Pioneered the ability to recapture, reposition, and retrieve the TAVI valve to ensure optimal placement6
  • Provides earlier leaflet functionality with its intra-annular position6
  • Avoids the need for rapid pacing during deployment6,7  
  • Offers controlled deployment because of Portico’s continuous hemodynamic stability—therefore requiring a less hurried deployment6,8
  • Involves only a simple prep: 2 short 10-second rinses (total 20 seconds)7
  • Has a contoured leaflet design that allows for optimal coaptation in either round or elliptical annulus

PROVIDING STABLE HEMODYNAMICS

Hemodynamic stability is a key feature of the Portico valve, since its leaflets function at partial deployment.6 The potential advantages of this include:

  • No need for rapid pacing
  • Minimized loss in hemodynamic pressure5
  • The ability to assess placement before full release
  • Performance more like a natural heart valve with Portico’s unconstricted valve leaflet opening5


Portico inserted into aortic valve

INNOVATIVE LOADING AND DELIVERY SYSTEM

The Portico loading system’s intuitive, ergonomic features enhance placement and positioning by allowing the implanter to:

  • Reposition and recapture the valve as needed
  • Assess valve placement before fully disengaging the release lever

Portico loading control handle

References

1. Søndergaard L. How Portico helps solve challenging cases: horizontal aorta and calcified annulus. Webinar March 4, 2016.
2. Data on file at Abbott. Document 90237740.
3. Taramasso M, Denegri A, Kuwata S, et al. Feasibility and safety of transfemoral sheathless Portico aortic valve implantation: preliminary results in a single center experience. Catheter Cardiovasc Interv. 2018;91(3):533-539. doi: 10.1002/ccd.27100.
4. Agnifili M, Brambilla N, Testa L, et al. Use of the Solopath re-collapsible balloon access system for troublesome femoral access with the Portico transcatheter valve. Radcliffe Cardiology. June 2015.
5. Bedogni F. Aortic valve replacement. JESFC2018.
6. Möllmann H, Linke A, Holzhey DM, et al. Portico TF EU Pre-CE Mark 30-day outcomes for all 4 valve sizes. J Am Coll Cardiol Interv. 2017;10:1538–1547.
7. Portico IFU.
8. Agnifili M, Brambilla N, Testa L, et al. Use of the Solopath re-collapsible balloon access system for troublesome femoral access with the Portico transcatheter valve. Radcliffe Cardiology. June 2015.

TAVI OUTCOMES WITH PORTICO

The Portico-1 post-market clinical study examined 941 high-risk patients. The data revealed excellent 30-day outcomes during transcatheter aortic valve implantation (TAVI).5

EXCELLENT CLINICAL OUTCOMES

Portico I data revealed low rates of all-cause mortality and disabling stroke, and very low clinically significant paravalvular leak (PVL). Portico’s hemodynamic performance yielded a single-digit gradient.5

 

Excellent 30-day outcomes


References

*A new permanent pacemaker was implanted in 161 patients, representing 17.1% of all patients regardless of pacemaker status at baseline and 18.7% of patients with no prior pacemaker.
1. Søndergaard L. How Portico helps solve challenging cases: horizontal aorta and calcified annulus. Webinar March 4, 2016.
2. Data on file at Abbott. Document 90237740.
3. Taramasso M, Denegri A, Kuwata S, et al. Feasibility and safety of transfemoral sheathless Portico aortic valve implantation: preliminary results in a single center experience. Catheter Cardiovasc Interv. 2018;91(3):533-539. doi: 10.1002/ccd.27100.
4. Agnifili M, Brambilla N, Testa L, et al. Use of the Solopath re-collapsible balloon access system for troublesome femoral access with the Portico transcatheter valve. Radcliffe Cardiology. June 2015.
5. Maisano, Francesco, et al. Early commercial experience from transcatheter aortic valve implantation using Portico bioprosthetic valve: 30 day outcomes in a multicentre PORTICO-1 study. Euro Intervention, 2018;14.

PORTICO VALVE AND RELATED PRODUCTS

Portico Transcatheter Aortic Valve System

Model Number

Valve Size (mm)

Annulus Range (mm)

Area Range (mm2)

Perimeter Range (mm)

PRT-23

23

19-21

277-346

60-66

PRT-25

25

21-23

338-415

66-73

PRT-27

27

23-25

405-491

72-79

PRT-29

29

25-27

479-573

79-85

References

1. Søndergaard L. How Portico helps solve challenging cases: horizontal aorta and calcified annulus. Webinar March 4, 2016.
2. Data on file at Abbott. Document 90237740.
3. Taramasso M, Denegri A, Kuwata S, et al. Feasibility and safety of transfemoral sheathless Portico aortic valve implantation: preliminary results in a single center experience. Catheter Cardiovasc Interv. 2018;91(3):533-539. doi: 10.1002/ccd.27100.
4. Agnifili M, Brambilla N, Testa L, et al. Use of the Solopath re-collapsible balloon access system for troublesome femoral access with the Portico transcatheter valve. Radcliffe Cardiology. June 2015.

AP2946629-WBO Rev. A

Abbott Logo

Information contained herein for distribution outside the U.S. only.

CAUTION: These products are intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use, inside the product carton (when available) or online for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events.
Illustrations are artist's representations only and should not be considered as engineering drawings or photographs.
Unless otherwise specified, all product names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company. ™ Indicates a trademark of the Abbott group of companies. ‡ Indicates a third party trademark, which is property of its respective owner.

© 2020 Abbott. All Rights Reserved.

MAT-2001111 v1.0

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.

True
accessibility
© 2016 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

YESNO
accessibility

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.

YESNO
accessibility
© 2016 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

YESNO